JA3-WP4

Home  /  Outputs   /  JA3-WP4

The final project plan of the assessment on “Bioresorbable Stents in cardiovascular indications (coronary artery disease)” and the comments provided by the external experts and the manufacturers are now available. OTCA16 Project Plan HERE OTCA16 External Expert and Manufacturer Comments HERE

We are pleased to announce that the joint rapid assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin” is available. The health technologies assessed include rtCGM

[vc_row][vc_column][vc_column_text]This is the final project plan of the assessment on “High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer” and the comments provided by an external expert during scoping. Project Plan_HIFU_final Project Plan external reviewer comments and authors' answers[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row]

The final project plan of the assessment on “Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems” and the comments provided by the external experts and the manufacturers are now available. OTJA08_Project_Plan_CGM_and_FGM OTJA08_Compiled_comments_answers_PP_external_experts_manufacturers

Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery This is the final project plan of the assessment on “Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery” and the comments

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)". This is a revised version of the report originally posted on January

Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint® This is the assessment of the relative effectiveness of MammaPrint® - Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)". The final version of the assessment was published in January 2018.